Abstract: A guide assembly comprises a grooved mandrel having a first end adapted for coupling or connecting, a second end, and having a spiral groove and a set of ring grooves on an external surface of the grooved mandrel. The guide assembly comprises a guide shoe concentric to at least the second end of the grooved mandrel and an annular fastener that fastens the guide shoe to the grooved mandrel.

Abstract: Systems and methods for using machine learning to dynamically assess the likelihood that a shipping agreement will be successfully fulfilled. According to certain aspects, an electronic device may receive order data associated with the shipping agreement, wherein the electronic device may input the order data into a machine learning model which outputs a likelihood that the shipping agreement will be successfully fulfilled. The electronic device may enable a customer computing device to access this information and facilitate communications or corrective actions.

Abstract: A guide assembly comprises a grooved mandrel having a first end adapted for coupling or connecting, a second end, and having a spiral groove and a set of ring grooves on an external surface of the grooved mandrel. The guide assembly comprises a guide shoe concentric to at least the second end of the grooved mandrel and an annular fastener that fastens the guide shoe to the grooved mandrel.

Abstract: A string guide comprising an upper mandrel, a lower muleshoe guide concentric to a lower portion of the upper mandrel, and an annular fastener internal to the lower muleshoe guide that fastens the lower muleshoe guide to the upper mandrel. When the guide encounters an obstruction (e.g., a packer bore or liner top), the weight of equipment above the lower muleshoe guide elastically deforms the annular fastener which drives the lower muleshoe guide up the upper mandrel. As the lower muleshoe guide travels up the upper mandrel, internal lugs of the muleshoe guide ride a spiral groove on the upper mandrel to rotate the lower muleshoe guide around the upper mandrel.

Abstract: A string guide comprising an upper mandrel, a lower muleshoe guide concentric to a lower portion of the upper mandrel, and an annular fastener internal to the lower muleshoe guide that fastens the lower muleshoe guide to the upper mandrel. When the guide encounters an obstruction (e.g., a packer bore or liner top), the weight of equipment above the lower muleshoe guide elastically deforms the annular fastener which drives the lower muleshoe guide up the upper mandrel. As the lower muleshoe guide travels up the upper mandrel, internal lugs of the muleshoe guide ride a spiral groove on the upper mandrel to rotate the lower muleshoe guide around the upper mandrel.

Abstract: A compact, recyclable dental flossing device in the form of a multi-layered elongated filament or strip of a resin which has physical characteristics such that, when elongated or drawn to stop, possesses a substantially increased length and tensile strength and a reduced thickness suitable for flossing teeth.

Abstract: A compact, recyclable dental flossing device in the form of a multi-layered elongated filament or strip of a resin which has physical characteristics such that, when elongated or drawn to stop, possesses a substantially increased length and tensile strength and a reduced thickness suitable for flossing teeth.

Abstract: A sphygmomanometer with a cuff for use on a patient wrist, upper or lower arm incorporates an inflatable bladder and a support structure. The cuff is subdivided into two sections. The first section holds the bladder against an arterial side of the limb, while the second section abuts a non-arterial side of the limb and is mechanically coupled to the support structure. When the cuff is attached to the patient limb, the bladder is positioned to avoid receiving a gravitational force caused by the weight of the limb. Rather, the gravitational force is absorbed by the support structure in an interior area of the cuff removed from the bladder.

Abstract: A compact, recyclable dental flossing device in the form of a multi-layered elongated filament or strip of a resin which has physical characteristics such that, when elongated or drawn to stop, possesses a substantially increased length and tensile strength and a reduced thickness suitable for flossing teeth.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.

Abstract: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The compounds of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

Abstract: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formulas I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein B, R1, R2, R3 and x are described herein.

Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein.